Promoter hypermethylation in circulating blood cells identifies prostate cancer progression

International Journal of Cancer

Volumn 122, Issue 4, 2008, Pages 952-956

  Rouprêt, Morgan ^a,b,c   Hupertan, Vincent ^b   Catto, James W F ^a   Yates, David R ^a   Rehman, Ishtiaq ^a   Proctor, Laura M ^a   Phillips, Joshua ^a   Meuth, Mark ^a   Cussenot, Olivier ^b   Hamdy, Freddie C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

DNA methylation; Epigenetic; Prostate cancer; PSA recurrence

Indexed keywords

CELL DNA; TUMOR MARKER; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; RASSF1 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BETA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; APC GENE; ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; GENE; GSTP1 GENE; HIGH RISK PATIENT; HUMAN; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RARBETA GENE; RASSF1A GENE; VENOUS BLOOD; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; RISK FACTOR; TUMOR EMBOLISM; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; DNA METHYLATION; GENES, APC; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 38349049165     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23196     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
3. Hessels D, Verhaegh GW, Schalken JA, Witjes JA. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn 2004;4:513-26.
4. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-301.
5. Lattouf JB, Saad F. Digital rectal exam following prostatectomy: is it still necessary with the use of PSA? Eur Urol 2003;43:333-6.
6. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576-81.
7. Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, Nelson WG. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 2004;46:698-708.
8. Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol 2003;170:2444-52.
9. Swindle PW, Kattan MW, Scardino PT. Markers and meaning of primary treatment failure. Urol Clin North Am 2003;30:377-401.
10. Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, de la Taille A, Rozet F, Cathelineau X, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 2007;13:1720-5.
11. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005;11: 8321-5.
12. Greene FL, Page DL. Genitourinary sites. Prostate. AJCC cancer staging manual, 6th edn. New York: Springer, 2002.309-17.
13. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005;11:6582-8.
14. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004;10:8472-8.
15. Chu DC, Chuang CK, Fu JB, Huang HS, Tseng CP, Sun CF. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma. J Urol 2002;167: 1854-8.
16. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514-9.
17. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005;114037-43.
18. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.